Fig. 7: Rafoxanide alters mitochondrial activity in CRC patient-derived samples.
From: Rafoxanide disrupts mitochondrial homeostasis through VDAC1 modulation in colorectal cancer cells
A Lollipop plot showing the downregulated (blue) and upregulated (red) proteomic pathways ranked by -log10 false discovery rate (−log10FDR), calculated on the set of significantly downregulated and upregulated mitochondrial proteins from human CRC explants treated (n = 6) or not (n = 6) with rafoxanide (10 μM) for 16 h. B Lollipop plot showing the downregulated (blue) and upregulated (red) proteomic pathways ranked by -log10 false discovery rate (-log10FDR), calculated from the set of differentially expressed mitochondrial proteins in CRC patient-derived intestinal organoids treated with rafoxanide (10 μM, n = 3) or vehicle (DMSO, n = 3) for 24 h.
